3rslkEbYP

220 Drogas no Brasil – Entre a saúde e a justiçaHANEY, M., WARD, A. S., COMER, S. D., FOLTIN, R. W., FISCHMAN, M. W. Abstinencesymptoms following smoked Cannabis in humans. Psychopharmacology 141:395-404, 1999.HART, C. L., W. G., van Gorp, HANEY, M., FOLTIN, R. W., FISCHMAN, M. W. Effectsof acute smoked cannabis on complex cognitive performance. Neuropsychopharmacology25:757–65, 2001.HART, C. L., ILAN, A. B., GEVINS, A., GUNDERSON, E. W., ROLE, K., COLLEY, J.,FOLTIN, R.W. Neurophysiological and cognitive effects of smoked Cannabis in frequent users.Pharmacology, Biochemistry and Behavior 96: 333-341, 2010.HASHIBE, M., STRAIF, K., TASHKIN, D. P., MORGENSTERN, H., GREELAND, S.,ZHANG, Z. F. Epidemiologic review of Cannabis use and cancer risk. Alcohol. 35: 265-275,2005.HEISHMAN, S. J., ARASTEH, K., STITZER, M. L. Comparative effects of alcohol and Cannabison mood, memory and performance. Pharmacol Biochem Behav 58:93-101, 1997.HERKENHAM, M., LYNN, A. B., LITTLE, M. D., JOHNSON, M. R., MELVIN, L. S., B.R., de Costa, RICE, K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci.USA 87: 1932-1936, 1990.HUNAULT, C. C., MENSINGA, T. T., BÖCKER, K. B., SCHIPPER, C. M., KRUIDE-NIER, M., LEENDERS, M. E., I., deVries, MEULENBELT, J. Cognitive and psychomotoreffects in males after smoking a combination of tobacco and cannabis containing up to 69mgdelta-9-tetrahydrocannabinol (THC). Psychopharmacology 204:85–94, 2009.IARC. IARC Working group on the evaluation of carcinogenic risks to humans. Tobacco smokeand involuntary smoking., I. P. Editors., Editor 2004, WHO: Lyon.IVERSEN, L.L. The science of cannabis. New York: Oxford University Press, 2000.IZZO, A., BORRELLI, F., CAPASSO, R., MARZO, V di., MECHOULAM, R. Non-psychotropicplant cannabinoids:new therapeutic opportunities from an ancient herb. Trends in PharmacologicalSciences 30: 515-527, 2010.KREBS, T. S., & JOHANSEN, P.-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysisof randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002, 2012.KREBS, T. S., & JOHANSEN, P.-Ø. Psychedelic sand mental health: a population study. Plo-SOne, 8(8), e63972, 2013.LANE, S. D., CHEREK, D. R., TCHEREMISSINE, O. V., LIEVING, L. M., PIETRAS, C.J. Acute Cannabis effects on human risk taking. Neuropsychopharmacology 30:800–9, 2005.LUCAS, P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. JPsychoactiveDrugs, 44(2): 125-33, 2012.MELAMEDE, R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct Journal2: p. 21, 2005.MITHOEFER, M. C., WAGNER, M. T., MITHOEFER, A. T., JEROME, L., DOBLIN,R. The safety and effi cacy of {+/-}3,4-methylenedioxy-methamphetamine-assisted psychotherapyin subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomizedcontrolled pilot study. J Psychopharmacol 25: 439–452, 2011.MORENO, F. A., WIEGAND, C. B., TAITANO, E. K.,& DELGADO, P. L. Safety, tolerability,and effi cacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal ofClinical Psychiatry, 67(11), 1735-40, 2006.